These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9135550)

  • 81. VSV G protein induces murine cytolytic T lymphocytes.
    Reiss CS; Chen SS; Huang AS; Doherty R
    Microb Pathog; 1986 Jun; 1(3):261-7. PubMed ID: 2854599
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.
    Dittmer U; Brooks DM; Hasenkrug KJ
    J Virol; 1998 Aug; 72(8):6554-8. PubMed ID: 9658099
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A gene therapy model for retrovirus-induced disease with a viral env gene: expression-dependent resistance in immunosuppressed hosts.
    Kitagawa M; Aizawa S; Sado T; Yamaguchi S; Suzuki T; Hirokawa K; Ikeda H
    Leukemia; 2001 Nov; 15(11):1779-84. PubMed ID: 11681421
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Expression and CTL recognition of cloned subgenomic fragments of Moloney murine leukemia virus in murine cells.
    Flyer DC; Burakoff SJ; Faller DV
    Surv Immunol Res; 1985; 4(2):168-72. PubMed ID: 3875887
    [No Abstract]   [Full Text] [Related]  

  • 85. B lymphocyte activation by coinfection prevents immune control of friend virus infection.
    Marques R; Antunes I; Eksmond U; Stoye J; Hasenkrug K; Kassiotis G
    J Immunol; 2008 Sep; 181(5):3432-40. PubMed ID: 18714015
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The envelope of Mason-Pfizer monkey virus has immunosuppressive properties.
    Blaise S; Mangeney M; Heidmann T
    J Gen Virol; 2001 Jul; 82(Pt 7):1597-1600. PubMed ID: 11413370
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comment on "Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors".
    Hasenkrug KJ; Dittmer U
    J Immunol; 2010 Aug; 185(3):1349; author reply 1349 - 50. PubMed ID: 20660355
    [No Abstract]   [Full Text] [Related]  

  • 88. Induction of protective CTL responses in newborn mice by a murine retrovirus.
    Sarzotti M; Robbins DS; Hoffman PM
    Science; 1996 Mar; 271(5256):1726-8. PubMed ID: 8596933
    [TBL] [Abstract][Full Text] [Related]  

  • 89. CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection.
    Kraft AR; Krux F; Schimmer S; Ohlen C; Greenberg PD; Dittmer U
    Blood; 2007 Apr; 109(7):2982-4. PubMed ID: 17148590
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes.
    Hunsmann G; Schneider J; Schulz A
    Virology; 1981 Sep; 113(2):602-12. PubMed ID: 6943864
    [No Abstract]   [Full Text] [Related]  

  • 91. Gender-related differences in susceptibility, early virus dissemination and immunosuppression in mice infected with Friend murine leukaemia virus variant FIS-2.
    Bruland T; Dai HY; Lavik LAS; Kristiansen LI; Dalen A
    J Gen Virol; 2001 Aug; 82(Pt 8):1821-1827. PubMed ID: 11457987
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Expression of endogenous viral antigens during immune response.
    Wecker E
    Med Microbiol Immunol; 1977; 164(1-3):231-8. PubMed ID: 202853
    [No Abstract]   [Full Text] [Related]  

  • 93. Elucidation of mode of retroviral-inhibitory effects of imexon through use of immune competent and severe combined immune deficiency (SCID) mice.
    Morrey JD; Mead JR; Warren RP; Okleberry KM; Burger RA; Sidwell RW
    Antiviral Res; 1992 Mar; 17(3):223-33. PubMed ID: 1314537
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Defects in the function of dendritic cells in murine retroviral infection.
    Gabrilovich DI; Patterson S; Harvey JJ; Woods GM; Elsley W; Knight SC
    Adv Exp Med Biol; 1995; 378():469-72. PubMed ID: 8526120
    [No Abstract]   [Full Text] [Related]  

  • 95. Immunological regression of metastatic cancer in the liver as a result of "in vivo xenogenization".
    Suzuki Y; Okayasu T; Morikawa K; Hamada J; Sugawara M; Oikawa T; Hosokawa M; Kobayashi H
    Biotherapy; 1990; 2(1):41-9. PubMed ID: 2205257
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Analysis of the distribution of neuropathogenic retroviral antigens following PVC211 or A8-V infection.
    Nakai R; Takase-Yoden S; Watanabe R
    Microbiol Immunol; 2005; 49(12):1075-81. PubMed ID: 16365533
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Transgenic approach to hepatitis B virus liver damage.
    McDonnell WM; Van Dyke RW
    Hepatology; 1991 Jan; 13(1):191-3. PubMed ID: 1988341
    [No Abstract]   [Full Text] [Related]  

  • 98. Human cancers and viruses: a hypothesis for immune destruction of tumours caused by certain enveloped viruses using modified viral antigens.
    Ngu VA
    Med Hypotheses; 1992 Sep; 39(1):17-21. PubMed ID: 1435387
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Endogenous retroviral envelope antigens recognized by B lymphocytes during graft-versus-host reaction.
    Portis JL
    Tohoku J Exp Med; 1994 May; 173(1):83-9. PubMed ID: 7809913
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Immunogenic properties of retroviral protein P15E from drug-treated murine mastocytoma P815.
    Grohmann U; Fioretti MC; Binaglia L; Belladonna ML; Bianchi R; Puccetti P
    Int J Cancer; 1993 Sep; 55(2):344-50. PubMed ID: 7690350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.